Zhen Ge

Angiographic Findings and Post–Percutaneous Coronary Intervention Fractional Flow Reserve

J. Doh, Jinlong Zhang, Seokhun Yang, 2024, JAMA network open.

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial

Hongwei Qu, Yan Wang, B. Gill, 2024, The Lancet.

PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study

N. Tian, W. You, Zhi-ming Wu, 2024, American Heart Journal.

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

G. Dangas, R. Mehran, U. Baber, 2024, The Lancet.